HBS1L protein: a core GTPase of the ribosome rescue pathway and an emerging target in multiple disease areas

Author: Senior Product Manager of UA Views：20

This article focuses on the molecular characteristics and biological functions of HBS1L, systematically elaborating its molecular mechanisms as a translational GTPase that forms a complex with PELO to recognize stalled ribosomes, dissociate ribosomal subunits, and initiate the nonsense-mediated decay pathway. It analyzes its initiating role in ribosome-associated quality control and the physiological significance of clearing abnormal mRNAs and incomplete polypeptides, and explores the disease associations of HBS1L in FOCAD-deletion synthetic lethality in tumors, hemoglobin regulation, and hereditary eye diseases.

Recent Advances
Product Information

Recent Advances

HBS1L Protein: The Core GTPase of the Ribosome Rescue Pathway and an Emerging Target Across Multiple Disease Areas

Summary: This article focuses on the molecular characteristics and biological functions of HBS1L, systematically describing the molecular mechanism by which it, as a translation GTPase, forms a complex with PELO to recognize stalled ribosomes, dissociate ribosomal subunits, and initiate the nonsense-mediated decay pathway. It analyzes its initiating role in ribosome-associated quality control and the physiological significance of clearing abnormal mRNAs and incomplete polypeptides, and discusses the disease associations of HBS1L in FOCAD-deficient tumor synthetic lethality, hemoglobin regulation, and hereditary eye diseases.

I. Molecular Localization and Ribosome Rescue Function of HBS1L.

HBS1L is a translation GTPase whose classic partner is PELO, and together they constitute the core components of the ribosome rescue pathway. During protein translation, various factors can cause ribosomes to stall on mRNA and fail to continue elongation. If these stalled ribosomes are not cleared in a timely manner, they will cause the accumulation and aggregation of ribosomes and abnormal polypeptides, threatening cellular protein homeostasis. The HBS1L-PELO complex is precisely the core rescue machinery that responds to this crisis. From a molecular mechanism perspective, HBS1L, relying on its GTPase activity, drives the dissociation of the ribosomal large and small subunits after recognizing stalled ribosomes, creating conditions for subsequent cleavage of abnormal mRNA and release of nascent polypeptides. This function places HBS1L at the initiating position of the ribosome-associated quality control pathway, and its activity status directly determines whether stalled ribosomes can be effectively cleared.

II. Triggers of Ribosome Stalling and the Rescue Steps of HBS1L.

The conditions that trigger ribosome stalling are diverse, including mRNA damage, secondary structures, rare codons, breaks, and missing stop codons, all of which can cause ribosome translation stalling. The common feature of these triggers is that they disrupt the normal process of translation elongation or termination, preventing ribosomes from completing their established translation tasks. In the face of these different types of stalling events, the HBS1L-PELO complex plays a core role: after recognizing stalled ribosomes, the complex relies on GTPase activity to dissociate the ribosomal large and small subunits, cleave abnormal mRNA, release nascent polypeptides, and complete ribosome rescue. These steps are the initiating link of the ribosome-associated quality control pathway, and their successful completion is the prerequisite for subsequent degradation of abnormal mRNA and clearance of incomplete polypeptides.

III. Physiological Significance and Quality Control Value of HBS1L.

HBS1L-mediated ribosome rescue has clear physiological significance: it initiates the nonsense-mediated decay pathway to degrade abnormal mRNA, clears incomplete polypeptides, and avoids the accumulation and aggregation of ribosomes and abnormal polypeptides. The value of this function lies in maintaining the normal operation of the intracellular protein synthesis system——if stalled ribosomes accumulate in large amounts, they will not only occupy limited ribosomal resources but may also form toxic protein aggregates that interfere with the folding and function of normal proteins. Therefore, HBS1L is not only an emergency mechanism for occasional translation obstacles but also a routine quality control system that maintains protein homeostasis.

IV. Value of HBS1L as a Synthetic Lethal Target in FOCAD-Deficient Tumors.

In the field of tumor therapy, HBS1L demonstrates unique value as a synthetic lethal target. In tumors with 9p21 deletion, about one-third are accompanied by FOCAD co-deletion. After FOCAD inactivation, cells depend on the HBS1L-PELO ribosome rescue pathway for survival; pancreatic cancer, non-small cell lung cancer, and some hematologic malignancies all exhibit this dependency, and HBS1L-selective degraders are effective against such tumors. The molecular logic of this synthetic lethal relationship is that FOCAD deficiency significantly increases tumor cells' dependence on the ribosome rescue pathway. When HBS1L function is further inhibited, tumor cells die because they cannot effectively clear stalled ribosomes, whereas normal cells are relatively unaffected because FOCAD function is intact and their dependence on HBS1L is lower. This selective killing based on the gene deletion background provides a molecular basis for precision therapy of 9p21-deleted tumors.

V. Associations of HBS1L with Hematologic Diseases and Hereditary Eye Diseases.

In terms of hematologic diseases, polymorphisms in the HBS1L-MYB locus regulate fetal hemoglobin levels and are associated with the disease severity of β-thalassemia and sickle cell anemia. This association suggests that the genomic region where HBS1L is located is an important genetic node for the regulation of hemoglobin expression, and its polymorphic variants may alter disease phenotypes by affecting the persistent expression of fetal hemoglobin. In terms of hereditary eye diseases, biallelic loss-of-function mutations in HBS1L cause photoreceptor cell developmental defects and lead to retinal dystrophy. This finding extends the function of HBS1L from general translation quality control to the developmental processes of specific tissues, indicating that photoreceptor cells have a special dependence on the integrity of ribosome rescue function.

VI. Conclusion.

As the core member of the translation-related GTPase family responsible for stalled ribosome rescue, HBS1L plays an initiating role in ribosome-associated quality control through its molecular mechanism of forming a complex with PELO to recognize stalled ribosomes, dissociate ribosomal subunits, and initiate the nonsense-mediated decay pathway, and maintains cellular protein homeostasis by clearing abnormal mRNAs and incomplete polypeptides. Its value as a synthetic lethal target in FOCAD-deficient tumors, its genetic association in regulating fetal hemoglobin at the HBS1L-MYB locus, and its pathogenic role in retinal dystrophy caused by biallelic loss-of-function mutations together constitute the target landscape of HBS1L spanning both oncology and genetic disease directions.

In HBS1L-related basic research and drug development, high-quality recombinant HBS1L protein is a core tool for dissecting its GTPase activity, the assembly mechanism of its complex with PELO, and its ribosome recognition properties. To meet the needs of HBS1L functional research and exploration of ribosome rescue mechanisms, UIA provides HBS1L Protein, Human. This product is suitable for applications such as studies of HBS1L-PELO interactions and complex assembly mechanisms, in vitro analysis of HBS1L GTPase activity and its role in stalled ribosome recognition, binding activity evaluation and screening of HBS1L-selective degraders, and development of synthetic lethal strategies for FOCAD-deficient tumors.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next